Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy

被引:34
|
作者
Osipov, Arsen [1 ]
Nissen, Nicholas [2 ]
Rutgers, Joanne [3 ]
Dhall, Deepti [3 ]
Naziri, Jason [4 ]
Chopra, Shefali [3 ]
Li, Quanlin [1 ]
Hendifar, Andrew Eugene [1 ]
Tuli, Richard [4 ]
机构
[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA
[4] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
关键词
RANDOMIZED CONTROLLED-TRIAL; DUCTAL ADENOCARCINOMA; CURATIVE RESECTION; PROGNOSTIC-FACTORS; R1; RESECTIONS; HEAD CANCER; CHEMOTHERAPY; METAANALYSIS; RECURRENCE; PANCREATICODUODENECTOMY;
D O I
10.1245/s10434-017-6076-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA. We identified 105 patients with resected PDA. Pancreatic, anterior, bile duct, and posterior surgical resection margins (PM; posterior surface, uncinate and vascular groove) were identified. Three pathologists reviewed all archival surgical specimens and recategorized each margin as tumor at ink/transected, < 0.5, 0.5-1, > 1-2, or > 2 mm from the inked surface. The impact of these and other clinical variables was assessed on local control, disease-free survival (DFS), and overall survival (OS). Among all margins, PM clearance up to 2 mm was prognostic of DFS (p = 0.01) and OS (p = 0.01). Dichotomizing the PM at 2 mm revealed it to be an independent predictor of local recurrence-free survival [hazard ratio HR] 0.20, 95% confidence interval [CI] 0.048-0.881, p = 0.033), DFS (HR 0.46, 95% CI 0.22-0.96, p = 0.03), and OS (HR 0.31, 95% CI 0.14-0.74, p = 0.008). A margin status of > 2 mm was also prognostic of OS in patients who received adjuvant chemotherapy (HR 0.31, 95% CI 0.11-0.89, p = 0.03), however this difference was mitigated in patients receiving adjuvant chemoradiotherapy (HR 0.40, 95% CI 0.10-1.58, p = 0.19). These data highlight the clinical significance of the PM and the lack of significance of other resection margins. Clearance in excess of 2 mm should be considered to improve long-term clinical outcomes. The use of adjuvant radiotherapy should be strongly considered in patients with PMs < 2 mm.
引用
收藏
页码:3674 / 3682
页数:9
相关论文
共 50 条
  • [1] Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy
    Arsen Osipov
    Nicholas Nissen
    Joanne Rutgers
    Deepti Dhall
    Jason Naziri
    Shefali Chopra
    Quanlin Li
    Andrew Eugene Hendifar
    Richard Tuli
    [J]. Annals of Surgical Oncology, 2017, 24 : 3674 - 3682
  • [2] Redefining the positive margin in pancreatic cancer: Impact of distance on survival
    Osipov, Arsen
    Rutgers, Joanne K.
    Dhall, Deepti
    Naziri, Jason
    Chopra, Shefali
    Li, Quanlin
    Nissen, Nicholas N.
    Tuli, Richard
    Hendifar, Andrew Eugene
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Pattern of Failure, Margin Status and Adjuvant Therapy in Pancreatic Cancer: Impact on Survival
    Osipov, Arsen
    Rutgers, Joanne K.
    Dhall, Deepti
    Naziri, Jason
    Chopra, Shefali
    Li, Quanlin
    Nissen, Nicholas
    Hendifar, Andrew
    Tuli, Richard
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E5 - E6
  • [4] Adjuvant Therapy for Margin Positive Pancreatic Cancer
    Takahashi, C.
    Huston, J.
    Shridhar, R.
    Patel, A.
    Meredith, K.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S130 - S131
  • [5] Adjuvant therapy for margin positive pancreatic cancer.
    Takahashi, Caitlin
    Shridhar, Ravi
    Harris, Cynthia L.
    Lee, Justin
    Patel, Anjan Jayantilal
    Brown, Richard H.
    Huston, Jamie
    Kucera, Stephen
    Meredith, Ken Lee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Impact of Tumor Location on Long-Term Survival for Pancreatic Cancer
    Blackburn, Kyle Warren
    Hanna, Nader N.
    Williams, Richelle T.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2022, 235 (05) : S50 - S50
  • [7] Impact of Long-Term Adjuvant Chemotherapy With Gemcitabin for Resected Pancreatic Cancer
    Ishido, Keinosuke
    Toyoki, Yoshikazu
    Miura, Takuya
    Kudo, Daisuke
    Narumi, Shunji
    Hakamada, Kenichi
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S552 - S552
  • [8] Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer
    Asmita Chopra
    Mazen Zenati
    Melissa E. Hogg
    Herbert J. Zeh
    David L. Bartlett
    Nathan Bahary
    Amer H. Zureikat
    Joal D. Beane
    [J]. Annals of Surgical Oncology, 2021, 28 : 7759 - 7769
  • [9] Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer
    Chopra, Asmita
    Zenati, Mazen
    Hogg, Melissa E.
    Zeh, Herbert J., III
    Bartlett, David L.
    Bahary, Nathan
    Zureikat, Amer H.
    Beane, Joal D.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (12) : 7759 - 7769
  • [10] Long-term Adjuvant Chemotherapy Improves the Postoperative Survival in Pancreatic Cancer Patients With Positive Peritoneal Lavage Cytology
    Ohgi, K.
    Sugiura, T.
    Ashida, R.
    Yamada, M.
    Otsuka, S.
    Uesaka, K.
    [J]. PANCREAS, 2021, 50 (07) : 1087 - 1087